Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PURPLE trial of preoperative atezolizumab combinations for resectable colorectal liver metastases
2022-503044-40-00Phase 2Authorised
- Sponsor
- Universitätsmedizin Essen
- Start
- Aug 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in colorectal cancer liver metastasis (CRLM) comparing Tecentriq + tiragolumab with Tecentriq + Avastin (2 arms). Primary endpoint: Percentage of resected patients with complete or major pathological regression. Planned start Aug 2024; status: authorised.
02
Drugs
atezolizumabtiragolumabbevacizumab
03
Conditions
colorectal cancer liver metastasis (CRLM)
Beyond the preview
Go deeper on 2022-503044-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-503044-40-00.